Nivolumab Plus Stereotactic Body Radiotherapy in II and III Line of Patients With Metastatic Renal Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)
- Status
- TERMINATED
- Phase
- PHASE2
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition
- Status
- COMPLETED
- Phase
- N/A
Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer
- Status
- COMPLETED
- Phase
- PHASE2
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of Nivolumab for Advanced Cancers in India
- Status
- COMPLETED
- Phase
- PHASE4
An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed
- Status
- TERMINATED
- Phase
- PHASE1
PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC
- Status
- COMPLETED
- Phase
- PHASE2
Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk
- Status
- COMPLETED
- Phase
- PHASE2
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2